Boston Scient

Real-time Quotes | Nasdaq Last Sale

After Hours: 34.36 -0.05 -0.15% 19:54 12/04 EST
Corp Actions
Silk Road Medical Announces Changes to Board of Directors
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the appointment of Kevin Ballinger to the company's Board of Directors. Simultaneously, the company also announced the resignation of current board member, Ruoxi Chen. Both of these changes are effective immediately.
GlobeNewswire · 1d ago
Tarachi Appoints Michael Konnert as Chairman and Cameron Tymstra as CEO
Tarachi Appoints Michael Konnert as Chairman and Cameron Tymstra as CEO
CNW Group · 2d ago
Boston Scientific (BSX) to Divest BTG's Non-MedTech Arm
Zacks · 2d ago
Deep Brain Stimulation Devices Market to Register an Excellent CAGR of 11.6% by 2026; Increasing Prevalence of Neurological Disorders to Accelerate Market Revenue, says Fortune Business Insights(TM)
The global deep brain stimulation devices market size is expected to reach USD 1,676.8 million by 2026, exhibiting a CAGR of 11.6% during the forecast period. The growing awareness among the population concerning various neurological ailments will be a crucial factor in accelerating the deep brain stimulation (DBS) devices market revenue during the forecast period. The market in North America stood at USD 323.4 million in 2018 and is expected to flourish rapidly. The presence of major players in the region will uplift the deep brain stimulation devices market share.
GlobeNewswire · 3d ago
BriaCell Appoints Martin Schmieg to Board of Directors
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors.
GlobeNewswire · 3d ago
E-Healthcare Market Research Report by Type, by Type of Service, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19
, /PRNewswire/ --  Read the full report: The Global E-Healthcare Market is expected to grow from in 2019 to by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 18.06%.Market Segmentation & Coverage:This research report categorizes the E-Healthcare to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Type, the E-Healthcare Market studied across Clinical Decision Support Systems, e-Prescribing, Electronic Health Records, Health Information System, and Telemedicine. Based on Type of Service, the E-Healthcare Market studied across Adherence Monitoring, Diagnosis Services, Monitoring Services, Special Monitoring, and Vital Sign Monitoring. Based on End User, the E-Healthcare Market studied across Healthcare Consumers, Hospitals, and Insurance Companies. Based on Geography, the E-Healthcare Market studied across Americas, , and , & . The Americas region surveyed across , , , , and . The region surveyed across , , , , , , , , and . The , & region surveyed across , , , , , , , , , , and . Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global E-Healthcare Market including Aerotel Medical Systems, Ltd, AgaMatrix Inc., AliveCor, Inc., Allscripts Healthcare Solutions Inc., Apple Inc., AT&T Inc, Boston Scientific Corporation, Cerner Corporation, Cisco Systems Inc., Doximity Inc., EHealthLine.Com, Inc, Elsevier Inc., GE Healthcare, Johnson & Johnson Services, Inc., KareXpert, Inc., Koninklijke Philips NV, Medtronic PLC, Optum, Inc., Siemens Healthineers AG, and VICOMTECH. FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the E-Healthcare Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments1. What is the market size and forecast of the Global E-Healthcare Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global E-Healthcare Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global E-Healthcare Market?4. What is the competitive strategic window for opportunities in the Global E-Healthcare Market?5. What are the technology trends and regulatory frameworks in the Global E-Healthcare Market?6. What are the modes and strategic moves considered suitable for entering the Global E-Healthcare Market?Read the full report: About ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare:   US: (339)-368-6001 Intl: +1 339-368-6001 
PR Newswire - PRF · 3d ago
Boston Scientific to Sell BTG Specialty Pharma for $800 Million
Boston Scientific agreed to sell its BTG Specialty Pharmaceuticals for $800 million cash to affiliates of the Brussels drugmaker Serb SAS. · 3d ago
2020 Report on the EU5 Embolization Particles Market Outlook to 2025 - Featuring Boston Scientific, Sirtex Medical and Terumo Among Others -
The "EU5 Embolization Particles Market Outlook to 2025 - Microspheres, Radioembolization Particles, PolyVinyl Alcohol (PVA) Particles and Drug-Eluting Beads" report has been added to's offering.
BusinessWire · 4d ago
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BSX. Analyze the recent business situations of Boston Scient through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 26 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BSX stock price target is 43.46 with a high estimate of 50.00 and a low estimate of 40.00.
Institutional Holdings
Institutions: 1.16K
Institutional Holdings: 1.44B
% Owned: 100.30%
Shares Outstanding: 1.43B
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Advanced Medical Equipment & Technology
Healthcare Equipment & Supplies
Key Executives
Chairman/President/Chief Executive Officer/Director
Michael Mahoney
Chief Financial Officer/Executive Vice President
Daniel Brennan
Executive Vice President
Arthur Butcher
Executive Vice President
Joseph Fitzgerald
Executive Vice President
Edward Mackey
Executive Vice President
Ian Meredith
Executive Vice President
Jeffrey Mirviss
Executive Vice President
David Pierce
Executive Vice President
Eric Thepaut
Senior Vice President/Chief Information Officer
Jodi Eddy
Senior Vice President/General Counsel/Secretary
Desiree Ralls-Morrison
Senior Vice President/Director of Human Resources
Wendy Carruthers
Senior Vice President
Maulik Nanavaty
Senior Vice President
Scott Olson
Senior Vice President
Meghan Scanlon
Senior Vice President
John Sorenson
Lead Director/Independent Director
Edward Ludwig
Independent Director
Nelda Connors
Independent Director
Charles Dockendorff
Independent Director
Yoshiaki Fujimori
Independent Director
Donna James
Independent Director
Stephen MacMillan
Independent Director
David Roux
Independent Director
John Sununu
Independent Director
Ellen Zane
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BSX
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.
Hot Stocks

Webull offers kinds of Boston Scientific Corporation stock information, including NYSE:BSX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BSX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BSX stock methods without spending real money on the virtual paper trading platform.